Cargando…
Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease
Light chain deposition disease (LCDD) is a rare systemic disorder caused by the deposition of light chain immunoglobulins, which often results in renal impairment associated with either nephrotic syndrome or asymptomatic proteinuria. B-cell neoplasms, such as multiple myeloma and lymphoproliferative...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355407/ https://www.ncbi.nlm.nih.gov/pubmed/30101913 http://dx.doi.org/10.2169/internalmedicine.1018-18 |
_version_ | 1783391326306304000 |
---|---|
author | Kimura, Satoshi Ohkawara, Hiroshi Ogawa, Kazuei Tanaka, Mizuko Sano, Takahiro Harada-Shirado, Kayo Takahashi, Hiroshi Ueda, Koki Shichishima-Nakamura, Akiko Matsumoto, Hayato Ikeda, Kazuhiko Kazama, Junichiro James Hashimoto, Yuko Ikezoe, Takayuki |
author_facet | Kimura, Satoshi Ohkawara, Hiroshi Ogawa, Kazuei Tanaka, Mizuko Sano, Takahiro Harada-Shirado, Kayo Takahashi, Hiroshi Ueda, Koki Shichishima-Nakamura, Akiko Matsumoto, Hayato Ikeda, Kazuhiko Kazama, Junichiro James Hashimoto, Yuko Ikezoe, Takayuki |
author_sort | Kimura, Satoshi |
collection | PubMed |
description | Light chain deposition disease (LCDD) is a rare systemic disorder caused by the deposition of light chain immunoglobulins, which often results in renal impairment associated with either nephrotic syndrome or asymptomatic proteinuria. B-cell neoplasms, such as multiple myeloma and lymphoproliferative disorders, are well-known underlying diseases in LCDD. Some chemotherapy regimens have been reported, but both evidence-based treatment and management for LCDD have yet to be established. We herein report three cases of LCDD treated with lenalidomide-based therapy, resulting in hematologic responses accompanied by a significant reduction in proteinuria and improvement in the renal function. We recommend lenalidomide-based therapy for renal impairment caused by LCDD. |
format | Online Article Text |
id | pubmed-6355407 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | The Japanese Society of Internal Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-63554072019-02-01 Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease Kimura, Satoshi Ohkawara, Hiroshi Ogawa, Kazuei Tanaka, Mizuko Sano, Takahiro Harada-Shirado, Kayo Takahashi, Hiroshi Ueda, Koki Shichishima-Nakamura, Akiko Matsumoto, Hayato Ikeda, Kazuhiko Kazama, Junichiro James Hashimoto, Yuko Ikezoe, Takayuki Intern Med Case Report Light chain deposition disease (LCDD) is a rare systemic disorder caused by the deposition of light chain immunoglobulins, which often results in renal impairment associated with either nephrotic syndrome or asymptomatic proteinuria. B-cell neoplasms, such as multiple myeloma and lymphoproliferative disorders, are well-known underlying diseases in LCDD. Some chemotherapy regimens have been reported, but both evidence-based treatment and management for LCDD have yet to be established. We herein report three cases of LCDD treated with lenalidomide-based therapy, resulting in hematologic responses accompanied by a significant reduction in proteinuria and improvement in the renal function. We recommend lenalidomide-based therapy for renal impairment caused by LCDD. The Japanese Society of Internal Medicine 2018-08-10 2018-12-15 /pmc/articles/PMC6355407/ /pubmed/30101913 http://dx.doi.org/10.2169/internalmedicine.1018-18 Text en Copyright © 2018 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Case Report Kimura, Satoshi Ohkawara, Hiroshi Ogawa, Kazuei Tanaka, Mizuko Sano, Takahiro Harada-Shirado, Kayo Takahashi, Hiroshi Ueda, Koki Shichishima-Nakamura, Akiko Matsumoto, Hayato Ikeda, Kazuhiko Kazama, Junichiro James Hashimoto, Yuko Ikezoe, Takayuki Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease |
title | Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease |
title_full | Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease |
title_fullStr | Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease |
title_full_unstemmed | Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease |
title_short | Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease |
title_sort | lenalidomide as a beneficial treatment option for renal impairment caused by light chain deposition disease |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355407/ https://www.ncbi.nlm.nih.gov/pubmed/30101913 http://dx.doi.org/10.2169/internalmedicine.1018-18 |
work_keys_str_mv | AT kimurasatoshi lenalidomideasabeneficialtreatmentoptionforrenalimpairmentcausedbylightchaindepositiondisease AT ohkawarahiroshi lenalidomideasabeneficialtreatmentoptionforrenalimpairmentcausedbylightchaindepositiondisease AT ogawakazuei lenalidomideasabeneficialtreatmentoptionforrenalimpairmentcausedbylightchaindepositiondisease AT tanakamizuko lenalidomideasabeneficialtreatmentoptionforrenalimpairmentcausedbylightchaindepositiondisease AT sanotakahiro lenalidomideasabeneficialtreatmentoptionforrenalimpairmentcausedbylightchaindepositiondisease AT haradashiradokayo lenalidomideasabeneficialtreatmentoptionforrenalimpairmentcausedbylightchaindepositiondisease AT takahashihiroshi lenalidomideasabeneficialtreatmentoptionforrenalimpairmentcausedbylightchaindepositiondisease AT uedakoki lenalidomideasabeneficialtreatmentoptionforrenalimpairmentcausedbylightchaindepositiondisease AT shichishimanakamuraakiko lenalidomideasabeneficialtreatmentoptionforrenalimpairmentcausedbylightchaindepositiondisease AT matsumotohayato lenalidomideasabeneficialtreatmentoptionforrenalimpairmentcausedbylightchaindepositiondisease AT ikedakazuhiko lenalidomideasabeneficialtreatmentoptionforrenalimpairmentcausedbylightchaindepositiondisease AT kazamajunichirojames lenalidomideasabeneficialtreatmentoptionforrenalimpairmentcausedbylightchaindepositiondisease AT hashimotoyuko lenalidomideasabeneficialtreatmentoptionforrenalimpairmentcausedbylightchaindepositiondisease AT ikezoetakayuki lenalidomideasabeneficialtreatmentoptionforrenalimpairmentcausedbylightchaindepositiondisease |